

**Antidepressant-like effects of
3,4-methylenedioxymethamphetamine
(MDMA, ecstasy)**

Irina Majumder, MD

Discipline of Pharmacology

Faculty of Health Sciences

The University of Adelaide

Thesis submitted for the degree of

Doctor of Philosophy

at

The University of Adelaide, South Australia, Australia

April 2010

Table of Contents

List of Tables	viii
List of Figures	ix
Abstract	xi
Declaration	xiii
Acknowledgments.....	xv
Abbreviations.....	xvii
Chapter 1. Background	1
1.1. MDMA: an overview	1
1.2. Pharmacology of MDMA.....	6
1.2.1. Pharmacokinetics and metabolism of MDMA	6
1.2.2. The pharmacological action of MDMA in the brain	12
1.3. Immediate effects of MDMA in humans.....	15
1.3.1. Psychological MDMA effects.....	15
1.3.2. Tolerance to the subjective effects of MDMA	18
1.3.3. Physiological and side effects of MDMA.....	20
1.4. The subacute (rebound) effects of MDMA	23
1.5. Long-term effects of MDMA.....	26
1.6. Depression: an overview.....	31
1.6.1. Definition	31
1.6.2. Mechanisms of development of the depressive symptoms	33
1.6.2.1. Monoaminergic hypothesis of depression	34
1.6.2.1.1. Serotonergic system in depression.....	34

1.6.2.1.2. Noradrenergic system in depression	36
1.6.2.1.3. Dopaminergic system in depression	38
1.6.2.2. Cholinergic system in depression	38
1.6.2.3. Role of the hypothalamo-pituitary adrenal axis and cytokines in depression	39
1.6.2.4. Role of GABA and neuropeptides in depression	41
1.6.2.5. Neurotrophic hypothesis of depression	42
1.6.3. Mechanisms of action of clinically prescribed antidepressants	43
1.6.4. Genetics of depression	45
1.6.5. Depression as a comorbidity or a side effect of drugs	48
1.7. Preclinical studies of depression	49
1.7.1. Overview of the animal models of depression	49
1.7.2. Neurochemical models of depression	53
1.7.3. Environmental and social stress-induced models of depression	54
1.7.3.1. Learned Helplessness	54
1.7.3.2. Chronic Mild Stress	55
1.7.3.3. Social stress and maternal separation models	58
1.7.4. Olfactory bulbectomy	61
1.7.5. Animal tests of depression	61
1.7.5.1. Tail Suspension Test	62
1.7.5.2. Forced Swimming Test	62
1.7.5.3. Sucrose preference test	65
1.7.6. Genetic rodent models of depression	67
1.7.6.1. Fawn-Hooded rats	67
1.7.6.2. Wistar Kyoto rats	70
1.7.6.3. Flinders Sensitive Line rats	71
1.8. MDMA and depression: what are the links?	76
1.9. Summary, aims and hypotheses	82

Chapter 2. Effects of MDMA on behaviour in an animal model of depression.....	87
2.1. Introduction.....	87
2.2. Materials and methods.....	90
2.2.1. Animals.....	90
2.2.2. Drugs.....	91
2.2.3. Experimental protocol.....	91
2.2.3.1. Weighing of animals.....	91
2.2.3.2. Preparation and administration of drugs.....	92
2.2.3.3. Injections schedule.....	92
2.2.3.4. Forced Swimming Test.....	93
2.2.3.5. Sucrose preference test.....	94
2.2.3.6. Locomotor activity assessment.....	95
2.2.3.6.1. Equipment.....	95
2.2.3.6.2. Experimental protocol.....	95
2.2.4. Statistical analysis.....	96
2.3. Results.....	96
2.3.1. Weight.....	96
2.3.2. Locomotor activity.....	98
2.3.3. Forced Swimming Test.....	99
2.3.4. Sucrose preference test.....	101
2.4. Discussion.....	103
Chapter 3. Pharmacokinetics of MDMA in an animal model of depression.....	110
3.1. Introduction.....	110
3.2. Animals and methods.....	111
3.2.1. Animals.....	111
3.2.2. Drug preparation and administration.....	112

3.2.3. Experimental protocol.....	112
3.2.4. Determination of MDMA and MDA concentrations in cortex and blood	112
3.2.5. Statistical analysis.....	113
3.3. Results	113
3.4. Discussion	114
Chapter 4. Effects of repeated administration of MDMA on the cortical levels of 5-HT and 5-HIAA in an animal model of depression	116
4.1. Introduction	116
4.2. Animals and methods.....	118
4.2.1. Animals, drugs and experimental protocol	118
4.2.2. Measurement of 5-HT and 5-HIAA levels in cortex	118
4.2.3. Statistical analysis.....	119
4.3. Results	119
4.4. Discussion	120
Chapter 5. Effects of MDMA on mood in subjects with and without a predisposition to depression	124
5.1. Introduction	124
5.2. Subjects and methods	126
5.2.1. Subjects	126
5.2.2. Recruitment.....	127
5.2.2.1. Inclusion criteria	128
5.2.2.2. Exclusion criteria.....	129
5.2.3. Study testing schedule	130
5.2.3.1. Baseline session.....	130
5.2.3.2. Party session.....	131

5.2.4. Demographic data	132
5.2.5. Psychological assessment	133
5.2.5.1. Brief Symptom Inventory (BSI)	133
5.2.5.2. Beck Depression Inventory (BDI)	134
5.2.5.3. Profile of Mood States (POMS)	135
5.2.6. MDMA and nicotine exposure	135
5.2.7. Statistical analysis	136
5.3. Results	137
5.3.1. Demographic data	137
5.3.2. MDMA and nicotine exposure	142
5.3.3. Use of ecstasy and other substances at the party session	143
5.3.4. Psychological tests	144
5.3.4.1. Brief Symptom Inventory	144
5.3.4.2. Profile of Mood States	146
5.3.4.2.1. Total Mood Disturbance score	146
5.3.4.2.2. Tension/Anxiety scale	147
5.3.4.2.3. Depression/Dejection scale	150
5.3.4.2.4. Anger/Hostility scale	150
5.3.4.2.5. Vigour/Activity scale	150
5.3.4.2.6. Fatigue/Inertia scale	151
5.3.4.2.7. Confusion/Bewilderment scale	151
5.3.4.3. Beck Depression Inventory	151
5.3.5. Correlational analysis	152
5.4. Discussion	155
Chapter 6. Effects of MDMA on serotonergic function in users with and without a predisposition to depression	168
6.1. Introduction	168

6.2. Subjects and methods	171
6.2.1. Subjects	171
6.2.2. Measurement of 5-HT and 5-HIAA levels in platelet-rich plasma (PRP).....	171
6.2.3. Measurement of 5-HT uptake in platelet-rich plasma	172
6.2.4. Determination of the 5-HT transporter gene polymorphism.....	173
6.2.4.1. 5-HTTLPR (Insertion/deletion) assay	173
6.2.4.2. VNTR assay	174
6.2.5. Statistical analysis.....	175
6.3. Results	175
6.3.1. 5-HT and 5-HIAA levels in platelet-rich plasma	175
6.3.2. 5-HT uptake in platelet-rich plasma	175
6.3.3. Genotyping	176
6.3.3.1. 5-HTTLPR polymorphism	176
6.3.3.2. VNTR polymorphism.....	177
6.3.3.3. Correlational analysis	177
6.4. Discussion	179
 Chapter 7. Effects of MDMA on mood in ecstasy users based on their previous exposure to the drug.....	 183
7.1. Introduction	183
7.2. Subjects and methods	184
7.2.1. Subjects	184
7.2.2. Analysis protocol	184
7.2.3. Statistical analysis.....	185
7.3. Results	186
7.3.1. Demographic data	186
7.3.2. Psychological tests.....	188

7.3.2.1. Brief Symptom Inventory	188
7.3.2.2. Beck Depression Inventory.....	189
7.3.2.3. Profile of Mood States.....	189
7.4. Discussion.....	192
Chapter 8. Conclusion	197
8.1. Summary of findings	197
8.2. Limitations of the study	201
8.3. Future directions	204
References	207
Appendix 1. Publications in support of the thesis	243
Publications.....	243
Conference papers.....	243

List of Tables

TABLE 3.1. PHARMACOKINETIC AND METABOLIC CHARACTERISTICS OF MDMA AND MDA IN SD AND FSL RATS.....	114
TABLE 5.1. DEMOGRAPHIC DATA OF SUBJECTS WITH AND WITHOUT A PREDISPOSITION TO DEPRESSION	138
TABLE 5.2. ECSTASY USE BY SUBJECTS WITH AND WITHOUT A PREDISPOSITION TO DEPRESSION	139
TABLE 5.3. MINIMUM AND MAXIMUM VALUES FOR ECSTASY USE PARAMETERS.....	139
TABLE 5.4. LIFETIME AND CURRENT USE OF OTHER ILLICIT DRUGS BY SUBJECTS WITH AND WITHOUT A PREDISPOSITION TO DEPRESSION.....	140
TABLE 5.5. BRIEF SYMPTOM INVENTORY T-SCORES	145
TABLE 7.1. DEMOGRAPHIC DATA DISTRIBUTION BETWEEN GROUPS WITH DIFFERENT ECSTASY EXPOSURE	187
TABLE 7.2. BSI T-SCORES REPORTED BY ECSTASY USERS WITH DIFFERENT EXPOSURE TO THE DRUG	188

List of Figures

FIGURE 1.1 CHEMICAL STRUCTURES OF AMPHETAMINE, METHAMPHETAMINE, MDMA AND Mescaline	1
FIGURE 1.2. METABOLIC PATHWAYS OF MDMA	9
FIGURE 2.1. MEAN WEIGHT OF SD AND FSL RATS IN TREATMENT GROUPS THROUGHOUT THE EXPERIMENTAL PERIOD	97
FIGURE 2.2. MEAN TOTAL PEAK AREAS FOR THE LOCOMOTOR ACTIVITY TIME-RESPONSE CURVES OF SD AND FSL RATS IN THE SALINE, MDMA10 AND METH2 TREATMENT GROUPS AFTER DRUG ADMINISTRATION	98
FIGURE 2.3. TOTAL IMMOBILITY TIME IN THE FST AFTER ACUTE AND REPEATED DRUG ADMINISTRATION	100
FIGURE 2.4. CONSUMPTION OF THE 32% SUCROSE SOLUTION BY SD AND FSL RATS IN THE SALINE, MDMA5, MDMA10 AND METH2 TREATMENT GROUPS	102
FIGURE 3.1. MDMA AND MDA CONCENTRATIONS IN CORTEX AND WHOLE BLOOD SAMPLES IN SD AND FSL RATS	113
FIGURE 4.1. 5-HT AND 5-HIAA LEVELS IN THE CORTEX OF SD AND FSL RATS AFTER THREE WEEKS OF TREATMENT	120
FIGURE 5.1. BRIEF SYMPTOM INVENTORY RESULTS	144
FIGURE 5.2. PROFILE OF MOOD STATES TOTAL MOOD DISTURBANCE SCORES AT THE BASELINE AND PARTY SESSIONS	147
FIGURE 5.3. PROFILE OF MOOD STATE SCALES SCORES AT THE BASELINE SESSION	148
FIGURE 5.4. PROFILE OF MOOD STATE SCALES SCORES AT THE PARTY SESSION	149
FIGURE 5.5. BECK DEPRESSION INVENTORY SCORES	152

FIGURE 6.1. THE 5-HT UPTAKE IN PLATELETS IN SUBJECTS WITH AND WITHOUT A PREDISPOSITION TO DEPRESSION 176

FIGURE 7.1. PROFILE OF MOOD STATES TOTAL MOOD DISTURBANCE SCORES IN THE GROUPS WITH DIFFERENT ECSTASY EXPOSURE 190

FIGURE 7.2. PROFILE OF MOOD STATES DEPRESSION/DEJECTION SCORES IN THE GROUPS WITH DIFFERENT ECSTASY EXPOSURE 191

Abstract

3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a popular club drug that is abused worldwide. The main subjective effects of the drug include enhanced mood and self-esteem. Due to these effects, ecstasy may be used at higher rates by people with pre-existing mood disorders, or a predisposition to depression, in order to 'self-medicate' their state. This, in turn, may lead to more regular drug use, and, hence, a higher risk of side effects and negative impact on health. Moreover, some mechanisms of MDMA action in the brain are similar to those of clinically prescribed antidepressants, as the drug primarily affects the serotonin (5-HT) system. This suggests that the drug may have antidepressant-like activity.

The studies reported here, both preclinical and clinical, were designed to investigate possible antidepressant-like effects of MDMA in subjects with a predisposition to depression.

In the animal study, the effects of MDMA following single and repeated administration were compared between Sprague-Dawley and the Flinders Sensitive Line rat strains, the latter being a putative model of depression. The drug's effects on behaviour were assessed in the Forced Swimming Test, which is widely used to detect the depressive-like state in laboratory animals. Acute MDMA administration had a dose-dependent antidepressant-like effect that was more evident in the Flinders Sensitive Line animals. This effect was diminished following 3 weeks of repeated drug injection, possibly due to the development of tolerance. The chosen dosing regime didn't affect the cortical levels of 5-HT and its metabolite.

40 current ecstasy users participated in the clinical study. Predisposition to depression was assessed using a questionnaire (Brief Symptom Inventory) that determines the rates of distress in various psychological spheres. Mood scores and depressive symptoms were assessed when participants were drug-free and when they attended a social gathering. Twenty participants, with and without a predisposition to depression, who voluntarily chose to take a pill at a social gathering, were assessed 1 hour after drug consumption, and the mood disturbance and depressive symptoms were compared with participants who abstained from pill consumption. Ecstasy users with a predisposition to depression reported higher mood disturbance and more prominent depressive symptoms when they were not under the influence of the drug. At the party, mood was improved in all participants irrespective of whether they chose to consume a pill, whereas subjects predisposed to depression reported a relative decrease in depressive symptoms only after pill consumption, which may be considered as an antidepressant-like effect of the drug. Certain variants of the 5-HT transporter gene polymorphism were associated with higher depressive scores.

Analysis of the effects of different previous ecstasy exposure revealed that subjects with a greater number of pills consumed in their lifetime report more prominent positive effects following ecstasy consumption, which may explain their more frequent use.

In sum, an immediate antidepressant-like effect of MDMA was evident both in an animal model of depression and in users predisposed to depression. This may suggest the self-medicating potential of MDMA in subjects with a predisposition to depression.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Irina Majumder and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Date: _____

Irina Majumder

Acknowledgments

I am deeply grateful to my supervisors, Prof Jason White and A/Prof Rod Irvine for the opportunity to conduct such an interesting project, for their knowledge and wisdom, patience, immense academic and moral support and assistance throughout my PhD candidature. I could not have wished for better supervisors.

I would also like to thank some other members of Discipline of Pharmacology at the University of Adelaide who helped me at different stages of my research. Special thanks to Dr Abdallah Salem for assistance with the HPLC analysis, Dr Femke Buisman-Pijlman for help with the analysis of behavioural experiments and valuable advice on statistics, Dr Janet Coller and Daniel Barratt for assistance with genotyping, Emily Jaehne for collaboration with the animal study and Lynlea Simmonds for help with recruitment in the clinical study, and also Aaron Farquharson, Karen Nunez-Vas and Gordon Crabb who ensured that I had everything organised for my research.

Furthermore, I would like to thank Thomas Sullivan from the Discipline of Public Health of the University of Adelaide for conducting and explaining the Linear Mixed Model analysis of the results of this project, Mr Peter Felgate from Forensic Science SA for doing the LC-MS analysis of the saliva samples, Melanie Gentgall from the Pain and Anaesthesia Research Clinic for assistance during the initial steps of my clinical study, and Charlotte Chambers from “Rip It Up” magazine for assistance with recruitment.

I would also to thank Michael Rennie from PM Separations for valuable feedback on the quantitative analysis of samples, staff members of Animal Services at the Medical

School of the University of Adelaide, at the Institute of Medical and Veterinary Science at Gilles Plains, and at the University of Technology of Sydney, IMVS Toxicology and Haematology laboratories.

Furthermore, I would like to acknowledge the National Health and Medical Research Council for financial support of this project and the Faculty of Health Sciences for providing a travel grant which gave me an opportunity to present the results of my project at the 71st Annual Meeting of the College on Problems of Drug Dependence in the USA in June 2009.

To my family I owe my deepest gratitude for their love, support, encouragement and inspiration. I thank my parents, Elizaveta and Surjo, my brother Amit and my new family - Brenton, who were always there for me in good and bad times.

I dedicate this thesis to the loving memory of my late grandparents, Irina Nikolaevna and Vladimir Ivanovich Tsivenko, whose love, wisdom and dedication were the source of my achievements.

Abbreviations

⁰C – degrees Celsius

¹⁴C – radioactive carbon isotope

3 α ,5 α -THP – 3 α ,5 α -tetrahydroprogesterone

5-HIAA – 5-hydroxyindoleacetic acid

5-HT – serotonin (5-hydroxytryptamine)

5-HTT – serotonin transporter

5-HTTLPR – serotonin transporter linked polymorphic region

8-OH-DPAT – 8-hydroxy-2-(di-n-propylamino)tetralin

ACTH – adrenocorticotrophic hormone

AMPT – alpha-methylparatyrosine

ANOVA – analysis of variance

AUC – area under the curve

BDI – Beck Depression Inventory

BDNF – brain-derived neurotrophic factor

BSI – Brief Symptom Inventory

cAMP – cyclic adenosine monophosphate

CBF – cerebral blood flow

CH₃OH – methanol

CH₃COONa - sodium acetate

Ci – curie

cm – centimetre

C_{max} – peak concentration

CNS – central nervous system

COMT – catechol-O-methyltransferase

CREB – cAMP response element binding

CRF – corticotropin-releasing factor

CSF – cerebrospinal fluid

CYP – cytochrome P450

DA – dopamine

DAT – dopamine transporter

DFP – diisopropyl fluorophosphate

dGTP – deoxyguanosine triphosphate

DMT – dimethyltryptamine

DNA – deoxyribonucleic acid

dNTP – deoxyribonucleoside 5'-triphosphate

DOPAC – 3,4-dihydroxyphenylacetic acid

DSM-IV – Diagnostic and statistical manual of mental disorders (IV edition)

EDTA – ethylenediaminetetraacetic acid

FH – Fawn-Hooded

FRL – Flinders Resistant Line

FSL – Flinders Sensitive Line

FST – Forced Swimming Test

g – gram

GABA – gamma-aminobutyric acid

GHB – gamma-hydroxybutyric acid

h – hour

HHA – 3,4-dihydroxyamphetamine

HHMA – 3,4-dihydroxymethamphetamine

HMA – 4-hydroxy-3-methoxyamphetamine

HMMA – 4-hydroxy-3-methoxymethamphetamine

HPA – hypothalamo-pituitary axis

HPLC – high performance liquid chromatography

HPLC-ECD – high performance liquid chromatography with electrochemical detection

HVA – homovanillic acid

i.p. – intraperitoneal

IFN- α – interferon-alpha

IL – interleukin

IMVS – Institute of Medical and Veterinary Science

kg – kilogram

LC-MS – liquid chromatography mass spectrometry

LMM – Linear Mixed Model

LSD – lysergic acid diethylamide

M – mol/litre

MAO – monoamine oxidase

MAOI – monoamine oxidase inhibitor

MDA – 3,4-methylenedioxyamphetamine

MDD – major depressive disorder

MDEA – 3,4-methylenedioxyethylamphetamine

MDMA – (\pm)-3,4-methylenedioxymethamphetamine (ecstasy)

METH – methamphetamine

mg – milligram

MHPG – 3-methoxy-4-hydroxyphenylglycol

min – minute

ml – millilitre

mm – millimetre

mRNA – messenger ribonucleic acid

nA – nanoamper

NA – noradrenaline

NaCl – sodium chloride

NaH₂PO₄ – sodium dihydrogen phosphate

NAT – noradrenaline transporter

ng – nanogram

NMe₅-HT – N-methyl-serotonin

NPY – neuropeptide Y

OSA – octanesulphonic acid

p.o. – per os

PBS – phosphate buffered saline

PCA – perchloric acid

PCR – polymerase chain reaction

PMA – para-methoxyamphetamine

POMS – Profile of Mood States

PPP – platelet-poor plasma

PRP – platelet-rich plasma

PTSD – posttraumatic stress disorder

REM – rapid eye movement

RM – Repeated Measures

ROS – reactive oxygen species

s – second

SCL-90 – Symptom Checklist-90

SD – Sprague-Dawley

SEM – standard error of mean

SMH – self-medication hypothesis

SNRI – serotonin-noradrenaline reuptake inhibitor

SSRI – selective serotonin reuptake inhibitor

$T_{1/2}$ – half-life

TBE – tris/borate/EDTA

TCA – tricyclic antidepressant

TH – tyrosine hydroxylase

T_{max} – time when peak concentration is reached

TMD – Total Mood Disturbance

$TNF\alpha$ – Tissue Necrosis Factor alpha

TPH – tryptophan hydroxylase

Trp – tryptophan

U – unit

V – volt

VMAT₂ – vesicular monoamine transporter type 2

VNTR – variable-number-tandem-repeat

VTA – ventral tegmental area

WKY – Wistar Kyoto

y – year

μl – microlitre